Coherus BioSciences (CHRS) News Today $0.79 -0.01 (-1.80%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.06%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Two Sigma Investments LPTwo Sigma Investments LP reduced its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 80.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,138 shares of the biotecJune 13 at 3:07 AM | marketbeat.comCoherus BioSciences, Inc. (CHRS): A Bull Case TheoryJune 6, 2025 | insidermonkey.comCoherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer TherapeuticsJune 5, 2025 | finanznachrichten.deCoherus BioSciences, Inc. (NASDAQ:CHRS) Director Sells $73,991.12 in StockCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) Director Mats Wahlstrom sold 99,988 shares of the company's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $0.74, for a total value of $73,991.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 30, 2025 | marketbeat.comCoherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer TherapeuticsMay 30, 2025 | finance.yahoo.comCoherus To Partner With STORM On Development Of LOQTORZI/STC-15 CombinationMay 29, 2025 | nasdaq.comInsider Selling: Coherus BioSciences, Inc. (NASDAQ:CHRS) Director Sells 99,988 Shares of StockMay 29, 2025 | insidertrades.comCoherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)May 27, 2025 | finance.yahoo.comCoherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdlesMay 23, 2025 | investing.com5,283,292 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. acquired a new position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 5,283,292 shares of the biotechnology compaMay 22, 2025 | marketbeat.comStockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to SellStockNews.com cut shares of Coherus BioSciences from a "hold" rating to a "sell" rating in a research report on Tuesday.May 22, 2025 | marketbeat.comTang Capital Management LLC Has $5.04 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)Tang Capital Management LLC lifted its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 55.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,650,000 shares of the biotechnology company's stock aftMay 20, 2025 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Issues Quarterly Earnings ResultsCoherus BioSciences (NASDAQ:CHRS - Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10).May 14, 2025 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comCoherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...May 13, 2025 | finance.yahoo.comCoherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comCoherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comCoherus BioSciences (NASDAQ:CHRS) Cut to "Sell" at StockNews.comStockNews.com lowered Coherus BioSciences from a "hold" rating to a "sell" rating in a report on Friday.May 11, 2025 | marketbeat.comCoherus at The Citizens JMP Life Sciences: Strategic Oncology FocusMay 9, 2025 | investing.comCoherus to Report First Quarter 2025 Financial Results on May 12, 2025May 5, 2025 | globenewswire.comCoherus BioSciences (CHRS) to Release Earnings on ThursdayCoherus BioSciences (NASDAQ:CHRS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-coherus-biosciences-inc-stock/)May 3, 2025 | marketbeat.comXTX Topco Ltd Sells 426,074 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)XTX Topco Ltd cut its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 90.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,443 shares of the biotechnology company's stock after selling 426,07May 3, 2025 | marketbeat.comCoherus to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comCoherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Coherus BioSciences in a research report on Tuesday.May 1, 2025 | marketbeat.comCoherus reports promising cancer treatment resultsApril 29, 2025 | investing.comCoherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric CancerApril 29, 2025 | nasdaq.comCoherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025April 28, 2025 | globenewswire.comBirchview Capital LP Reduces Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)Birchview Capital LP lowered its holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 78.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 82,000 shares of the biotechnology company's stock after selling 290,000 shares during the perApril 28, 2025 | marketbeat.comCoherus Biosciences price target lowered to $1.05 from $1.50 at UBSApril 25, 2025 | markets.businessinsider.comCoherus BioSciences announces CCO Paul Reider’s resignationApril 24, 2025 | uk.investing.comCoherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Coherus BioSciences from a "hold" rating to a "sell" rating in a report on Tuesday.April 17, 2025 | marketbeat.comCoherus BioSciences: Cleaning The Balance Sheet And Developing New DrugsApril 17, 2025 | seekingalpha.comCoherus Biosciences completes divestiture of UDENYCA franchiseApril 15, 2025 | markets.businessinsider.comCoherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® FranchiseApril 14, 2025 | globenewswire.comCoherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated NotesApril 3, 2025 | nasdaq.comCoherus Biosciences announces repurchase of $170M of convertible notesApril 1, 2025 | markets.businessinsider.comCoherus Announces Repurchase of Approximately $170 Million of Convertible NotesApril 1, 2025 | markets.businessinsider.comLobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosedMarch 26, 2025 | nasdaq.comCoherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comStatutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True PositionMarch 24, 2025 | finance.yahoo.comA Closer Look At Coherus BioSciences' EarningsMarch 24, 2025 | uk.finance.yahoo.comCoherus BioSciences Full Year 2024 Earnings: Beats ExpectationsMarch 14, 2025 | finance.yahoo.comCoherus BioSciences, Inc. (CHRS): A Bull Case TheoryMarch 12, 2025 | insidermonkey.comCoherus BioSciences (NASDAQ:CHRS) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Coherus BioSciences in a report on Tuesday.March 12, 2025 | marketbeat.comQ4 2024 Coherus BioSciences Inc Earnings CallMarch 11, 2025 | uk.finance.yahoo.comTruist Financial Sticks to Their Buy Rating for Coherus Biosciences (CHRS)March 11, 2025 | markets.businessinsider.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | msn.comCoherus BioSciences (NASDAQ:CHRS) Posts Earnings Results, Misses Expectations By $0.34 EPSCoherus BioSciences (NASDAQ:CHRS - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.34).March 11, 2025 | marketbeat.comCoherus Biosciences to reduce headcount by 30%March 10, 2025 | markets.businessinsider.comCoherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.com Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Media Mentions By Week CHRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼1.210.88▲Average Medical News Sentiment CHRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼32▲CHRS Articles Average Week Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fulcrum Therapeutics News iTeos Therapeutics News Revance Therapeutics News MBX Biosciences News Checkpoint Therapeutics News Rezolute News Vigil Neuroscience News Solid Biosciences News Compass Therapeutics News ADC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRS Stock Free CHRS Stock Alerts